The quality program has not established and maintained appropriate monitoring systems.
Inspection Record
Musculoskeletal Transplant Foundation — FDA 483 Findings
Inspectors Jennifer Macmillan · Sarah M. ForneyThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
Environmental controls do not provide for adequate cleaning and disinfecting of rooms and equipment to ensure aseptic processing.
Adverse reactions involving a communicable disease related to HCT/Ps were not investigated.
Procedures for the cleaning of equipment were not established.
The quality program has not ensured that appropriate corrective actions relating to core CGTP requirements are taken and documented.
Procedures appropriate to meet core CGTP requirements for all steps that you perform in the manufacture of HCT/Ps were not followed.
Complaints were not reviewed and evaluated to determine if the complaint is related to an HCTIP deviation or adverse reaction and whether a report to FDA is required.
The complaint file did not contain sufficient information about each complaint for proper review and evaluation and did not c ontain sufficient information for determining whether the complaint is an iso lated event or represents a trend.
Adverse reactions which involved a communicable disease related to an HCT/P made available for distribution and were fatal or life threatening, resulted in permanent impairment or damage to the body, or necessitated medical or surgical intervention, were not reported to FDA.
HCT/Ps were not processed in a way that does not cause contamination or cross contamination during processing and that does not increase the risk of introduction, transmission, or spread of communicable disease.
HCTIP deviations relating to core CGTP requirements that occurred in your establishment were not reported to FDA.
Labeling procedures were not designed to ensure proper HCTIP identification and to prevent mix-ups.
Adverse reactions were not reported to FDA using form FDA 3500A within I 5 calendar days ofi nitial receipt of information.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- Nelson Laboratories, LLC2025-07-30 · US FDASimilar to finding 1 The quality program has not established and maintained appropriate monitoring systems.
- MD Tox Laboratory2025-01-28 · US FDASimilar to finding 6 Procedures appropriate to meet core CGTP requirements for all steps that you perform in the manufacture of HCT/Ps were not defined and followed.
A record as of the US FDA document published on 2024-01-17. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.